中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
24期
139-141
,共3页
肾康注射液%急性肾衰竭%疗效及安全性
腎康註射液%急性腎衰竭%療效及安全性
신강주사액%급성신쇠갈%료효급안전성
Renal injection%Acute renal failure%Efficacy and safety
目的:分析总结肾康注射液治疗急性肾衰竭的临床疗效及其安全性。方法随机收集2012年7月-2014年7月来该院就诊的80例急性肾衰竭患者,将其平分为对照组与实验组,两组均给予基础治疗,实验组加用肾抗注射液,观察两组患者在治疗之前与之后的临床症状和体征的改变,以及血肌酐(Scr)、肾小球滤过率[Cys-eGFR(Mac)]、血胱抑素(ScysC)、血钾(血K+)、血尿素氮(BUN)、尿钠、尿胱抑素/尿肌酐(尿CysC/CR)、尿蛋白/尿肌酐(尿ACR)的变化情况变化。结果治疗12 d之后,两组Cys-eGFR(Mac)、BUN、Scr、血K+、ScysC、尿钠、尿CysC/CR以及尿ACR明显改善,而实验组改善明显优于对照组(P<0.01),同时,实验组疗效明显优于对照组(P<0.05),差异具有统计意义。所有患者在治疗过程中均未出现不良反应。结论肾康注射液治疗急性肾衰竭的临床疗效明显,且不产生不良反应,其用药的安全性值得肯定,作为急性肾衰竭的治疗药物,可以广泛应用。
目的:分析總結腎康註射液治療急性腎衰竭的臨床療效及其安全性。方法隨機收集2012年7月-2014年7月來該院就診的80例急性腎衰竭患者,將其平分為對照組與實驗組,兩組均給予基礎治療,實驗組加用腎抗註射液,觀察兩組患者在治療之前與之後的臨床癥狀和體徵的改變,以及血肌酐(Scr)、腎小毬濾過率[Cys-eGFR(Mac)]、血胱抑素(ScysC)、血鉀(血K+)、血尿素氮(BUN)、尿鈉、尿胱抑素/尿肌酐(尿CysC/CR)、尿蛋白/尿肌酐(尿ACR)的變化情況變化。結果治療12 d之後,兩組Cys-eGFR(Mac)、BUN、Scr、血K+、ScysC、尿鈉、尿CysC/CR以及尿ACR明顯改善,而實驗組改善明顯優于對照組(P<0.01),同時,實驗組療效明顯優于對照組(P<0.05),差異具有統計意義。所有患者在治療過程中均未齣現不良反應。結論腎康註射液治療急性腎衰竭的臨床療效明顯,且不產生不良反應,其用藥的安全性值得肯定,作為急性腎衰竭的治療藥物,可以廣汎應用。
목적:분석총결신강주사액치료급성신쇠갈적림상료효급기안전성。방법수궤수집2012년7월-2014년7월래해원취진적80례급성신쇠갈환자,장기평분위대조조여실험조,량조균급여기출치료,실험조가용신항주사액,관찰량조환자재치료지전여지후적림상증상화체정적개변,이급혈기항(Scr)、신소구려과솔[Cys-eGFR(Mac)]、혈광억소(ScysC)、혈갑(혈K+)、혈뇨소담(BUN)、뇨납、뇨광억소/뇨기항(뇨CysC/CR)、뇨단백/뇨기항(뇨ACR)적변화정황변화。결과치료12 d지후,량조Cys-eGFR(Mac)、BUN、Scr、혈K+、ScysC、뇨납、뇨CysC/CR이급뇨ACR명현개선,이실험조개선명현우우대조조(P<0.01),동시,실험조료효명현우우대조조(P<0.05),차이구유통계의의。소유환자재치료과정중균미출현불량반응。결론신강주사액치료급성신쇠갈적림상료효명현,차불산생불량반응,기용약적안전성치득긍정,작위급성신쇠갈적치료약물,가이엄범응용。
Objective To analysis the clinical curative effect of renal injection in treatment of acute renal failure and its safety. Methods Collected in July 2012 to July 2014 to our hospital of 80 patients with acute renal failure, renal injection of conventional treatment of 12 days, observe the patients before treatment and after the change of the clinical signs and symptoms, and serum creatinine (Scr), glomerular filtration rate (eGFR Cys - Mac), blood elf inhibition (ScysC), potassium (K+) blood, blood urea nitrogen (BUN), urine, urinary bladder, inhibition of sodium/urinary creatinine (urinary CysC/CR), urinary albumin/uric creatinine (urinary ACR) changes of the situation. Results Patients of Cys - eGFR (Mac) increase significantly after treatment, blood BUN, Scr, K +, sodium ScysC, urine, urinary CysC/CR and urinary ACR were significantly reduced, compared with before treatment, there are extremely significant difference (P< 0.01, with statistical significance. Of 40 cases, 15 cases were cured, 17 cases, 8 cases ineffective, the total effective rate was 80%. All patients with no adverse reactions occurred in the process of treatment. Conclusion The clinical curative effect of renal injection in treatment of acute renal failure, and do not produce adverse reactions, its drug safety credit, as a treatment for acute renal failure, can be widely used.